Hair loss treatments, specifically about the effectiveness of RU58841 compared to Pyrilutamide. Molecular weights and side effects were discussed in terms of efficacy and cost-effectiveness.
Kintor's KX826 (pyrilutamide) is ineffective at 0.5% and overpriced at 1%, leading to user frustration and calls for fair pricing. Users suggest sticking with proven treatments like Minoxidil and Finasteride.
Hair loss treatment using minoxidil and finasteride, with the user experiencing a shed after reducing the frequency of application and stopping microneedling. The user is now waiting for new hair growth and hoping to see similar results as before.
Microneedling can enhance hair growth when combined with treatments like minoxidil, especially topical minoxidil. Users discuss the benefits of continuing microneedling even when switching to oral minoxidil.
Relaxation may promote hair growth by reducing corticosterone, which affects hair follicle stem cells. Corticosteroids are used for alopecia areata, but their long-term use for androgenic alopecia is uncertain.
Comparing the effectiveness of minoxidil 5% and adenosine 0.75% for treating male androgenetic alopecia, and measuring patient satisfaction rate; results showed that adenosine is comparable to minoxidil but provides quicker results, however availability of products with adenosine is much less than those with minoxidil.
A user found a solution for Minoxidil-induced dandruff by using a custom NRF 11.121 mixture from a local pharmacy, which includes ingredients like Isopropyl palmitate and Cremophor RH 40. This formulation prevents dryness and allows better penetration when using hair shaders.
The user started using 5% liquid minoxidil on their scalp and noticed increased facial dryness and faster facial hair growth. They plan to reduce the application to once a day to see if it helps with the dryness.
The conversation is about a user's positive hair regrowth progress using 1.5 mg minoxidil and 1 mg finasteride over nearly five months. The user shares before-and-after photos, receiving praise and questions about their treatment and side effects.
Veradermics' extended-release oral minoxidil is expected to be commercially available in 2027-2028, while another company, Minx, may release a similar product sooner. VDPHL01 is considered more clinically validated compared to Minx.